As outcomes, two regulatory aspects stand out: both enhanced activity of RhoA, which is generally described as an oncogene, and diminished RhoB activity, suggesting a tumor suppressor role [49–51], are features of IR-resistant cells and intimately related to the survival of GBM patients (Fig. 1F). The gene discussed is RHOA; the disease is glioblastoma.